Kristen Quigley

Chief Operating Officer presso MOLECULAR TEMPLATES, INC.

53 anni

Health Technology

Consumer Services

Profilo

Kristen Quigley is currently the Chief Operating Officer at Molecular Templates, Inc. She started this position in 2023.
Prior to her current role, she worked as the Executive Director-Clinical Operations at Threshold Pharmaceuticals, Inc. Ms. Quigley completed her undergraduate degree at Washington University in St. Louis.

Posizioni attive di Kristen Quigley

Società	Posizione	Inizio
MOLECULAR TEMPLATES, INC.	Chief Operating Officer	02/08/2023

Tutte le posizioni attive di Kristen Quigley

Precedenti posizioni note di Kristen Quigley

Società	Posizione	Fine
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Chief Operating Officer	-

Vedi nel dettaglio l'esperienza di Kristen Quigley

Formazione di Kristen Quigley

Washington University in St. Louis

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Kristen Quigley

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
MOLECULAR TEMPLATES, INC.	Health Technology

Aziende private	1
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Health Technology